FROM ANALYTICAL CAPABILITY TO A COMPLETE CLINICAL PGx SERVICE IN JUST A FEW WEEKS
Laboratories that fail to embrace pharmacogenomics risk losing their competitive edge
Pharmacogenomics is no longer an emerging technology—it is becoming an essential component of modern healthcare. As healthcare systems across Europe continue integrating PGx into routine clinical practice, pharmacogenomics is rapidly establishing itself as a global standard of care.
Many laboratories already possess the analytical capabilities required for genetic testing, yet remain limited by the complexity of clinical interpretation, automated reporting and regulatory compliance.
r-Nomic® removes these barriers. It is a deployment-ready platform that dramatically reduces time-to-market, allowing laboratories to launch a complete pharmacogenomics service within weeks while delivering clinical value and regulatory confidence—without the complexity and cost of developing an in-house solution.
Compatible with your existing laboratory infrastructure
A complete high-performance pharmacogenomics solution
From genotyping to clinical report: How r-Nomic® works
r-Nomic® transforms your laboratory’s genetic data into clinically actionable pharmacogenomic reports without requiring additional infrastructure or internal software development. The platform integrates genotyping, clinical interpretation and fully branded reporting into a single automated workflow.
g-Nomic®: Advanced pharmacogenomic clinical decision support
As an optional extension, g-Nomic® provides real-time pharmacogenomic clinical decision support, enabling laboratories to offer clinicians a comprehensive prescribing solution that goes beyond the genetic report.
The PGx advantage that sets your laboratory apart
Why laboratories choose Eugenomic as their pharmacogenomics infrastructure
A robust platform designed to provide laboratories with immediate operational capability, outstanding clinical value and long-term scalability in pharmacogenomics.
Meeting the PGx standards expected by european laboratories
Choosing a PGx partner is both a strategic and regulatory decision
The transition to the European IVDR is reshaping the requirements for clinical software, IVD medical devices and pharmacogenomic reporting.
Selecting a pharmacogenomics infrastructure aligned with these evolving standards is essential for ensuring regulatory compliance, operational continuity and future scalability.
Eugenomic is actively committed to meeting the quality and regulatory standards that European laboratories increasingly expect from their pharmacogenomics partners.
🔹IVDR Class C – In vitro diagnostic medical device classification under European Regulation (EU) 2017/746.
🔹ISO 14971 – Risk management for medical devices.
🔹ISO 13485 – Quality management system for medical devices.
🔹PMS / PMCF – Post-market surveillance and post-market clinical follow-up.
🔹EUDAMED – European database for medical devices.
🔹Notified Body Certification – European conformity assessment currently in progress.
The best PGx report is one that clinicians can use immediately
Pharmacogenomic reports designed for real clinical practice
The value of a pharmacogenomic report lies in its ability to support clinical decision-making at the point of care. Every r-Nomic® report has been designed with this principle in mind.
🔹Intuitive therapeutic traffic-light system: A colour-coded classification instantly identifies medications that are appropriate, those requiring dose adjustment, and those associated with an increased risk of toxicity or clinically relevant interactions.
🔹Intelligent therapeutic grouping: Medications are organised by medical specialty and therapeutic class, allowing clinicians to compare pharmacological alternatives within a single view and make faster, better-informed treatment decisions.
🔹Evidence-based recommendations: Every recommendation is supported by internationally recognised clinical guidelines and regulatory agencies, including CPIC, DPWG, FDA and EMA.
Each recommendation includes both the level of evidence and its scientific reference, providing complete transparency for laboratories and confidence for clinicians.
🔹Built for everyday clinical practice: r-Nomic® reports are designed to be easily understood and applied by physicians across all specialties, enabling pharmacogenomic information to be incorporated into routine patient care without requiring advanced expertise in genomics.
CONFIGURABLE PANELS BY MEDICAL SPECIALTY
Pharmacogenomic panels tailored to every clinical specialty
Configurable pharmacogenomic panels designed to match the clinical focus and strategic objectives of each laboratory.
🔹Psychiatry: Antidepressants · ADHD · Antipsychotics
🔹Cardiology: Statins · Anticoagulants · Antiplatelet agents
🔹Oncology: DPYD · TPMT · NUDT15
🔹Preventive Medicine: Polygenic Risk Scores (PRS) · Nutrigenetics
🔹GLOBALpgx®: More than 200 medications across all medical specialties
🔹Custom Panel: Fully configurable genes and medications based on your laboratory’s portfolio
G-NOMIC®: THE OPTIONAL EXTENSION FOR LABORATORIES THAT WANT TO GO FURTHER
Extend your pharmacogenomics service beyond the clinical report
For most laboratories, the r-Nomic® report is the final deliverable.
For those looking to offer greater clinical value, g-Nomic® provides an optional extension that supports clinicians at the exact moment prescribing decisions are made.
By combining the patient’s genetic profile with current medication and lifestyle factors, g-Nomic® delivers real-time therapeutic decision support, helping clinicians optimise treatment decisions with greater confidence.
An enhanced pharmacogenomics service—without adding operational complexity to your laboratory.
What does g-Nomic® add to your laboratory's service offering?
Adding g-Nomic® provides laboratories with a clear competitive advantage over solutions focused solely on genotyping or report generation. It extends the laboratory's value proposition beyond the genetic report by delivering ongoing clinical decision support throughout the prescribing process.
Discover how to implement pharmacogenomics in your laboratory
Schedule a personalised consultation with one of Eugenomic’s PGx specialists and discover how to implement—or expand—clinical pharmacogenomics services without investing in your own infrastructure or building an internal clinical interpretation team.
During the meeting we will review:
🔹Your laboratory’s current workflow
🔹Available integration option
🔹White-label branding possibilities
🔹Laboratory-to-clinic workflow integration
🔹Real examples of pharmacogenomic reports
You can also contact us directly:
Phone: +34 932 922 963 / +34 682 902 773
Email: info@eugenomic.com
Thank you for your request
Out team will get back to you as soon as possible.
Frequently asked questions about implementing pharmacogenomics in clinical laboratories
-
Is in-house genotyping capability required to offer pharmacogenomics services?
Not necessarily.Eugenomic supports both laboratories with existing wet-lab capabilities and those wishing to introduce pharmacogenomics without developing their own analytical or interpretation infrastructure.
The solution can be implemented progressively according to each laboratory’s needs, capabilities and growth strategy.
-
Which genotyping technologies are compatible with r-Nomic®?
r-Nomic® is compatible with a wide range of genotyping technologies, including NGS, qPCR and SNP arrays, as well as leading platforms such as Illumina, Thermo Fisher Scientific and Agena Bioscience.
The platform supports direct import of CSV and Excel files for fully automated pharmacogenomic report generation.
-
What is the difference between performing genotyping and offering a complete clinical pharmacogenomics service?
Genotyping generates genetic data.
Clinical pharmacogenomics transforms those data into actionable clinical information by interpreting genetic variants, assigning phenotypes, correlating genes with medications and providing therapeutic recommendations that clinicians can readily apply in practice.
r-Nomic® delivers this complete interpretation and clinical reporting layer.
-
Can pharmacogenomic reports be customised with our laboratory's branding?
Yes.
All reports are generated in a fully white-label format, incorporating your laboratory’s logo, colours, typography and visual identity.
This allows your laboratory to maintain its own brand recognition and direct relationship with healthcare professionals.
-
How does r-Nomic® integrate with our Laboratory Information System (LIS)?
The platform can be accessed through a secure web portal or integrated directly into existing Laboratory Information Systems (LIS) via API.
This enables laboratories to automate report generation while maintaining their existing workflow.
-
What additional value does g-Nomic® provide beyond the standard pharmacogenomic report?
g-Nomic® complements r-Nomic® reports by providing real-time clinical decision support, including analysis of drug–drug, drug–gene and drug–lifestyle interactions during prescribing and therapeutic follow-up
-
Is r-Nomic® prepared for the new European IVDR regulatory framework?
Eugenomic is actively progressing towards IVDR Class C compliance, implementing the regulatory and quality standards required within the European market, including risk management, post-market surveillance, technical documentation and continuous process improvement.
-
What advantages does pharmacogenomics bring to a clinical laboratory's service portfolio?
Pharmacogenomics enables laboratories to expand their portfolio with high-value clinical services, differentiate themselves in an increasingly competitive market and respond to the growing demand for personalised medicine.
Beyond improving patient care, it creates new opportunities for collaboration with hospitals, clinics and healthcare professionals seeking to integrate pharmacogenomics into routine clinical practice.